Fig. 6From: Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysisForest plots showing odds ratio (OR) for overall response rate (ORR) comparing anti-EGFR antibody plus chemotherapy with control arm for the right-sided mCRC. CT, chemotherapy; BV, bevacizumabBack to article page